Context Therapeutics’ (CNTX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a report published on Monday, Benzinga reports. The firm currently has a $6.00 price objective on the stock.

Context Therapeutics Stock Performance

Shares of CNTX stock opened at $2.08 on Monday. Context Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.75. The firm has a market capitalization of $156.00 million, a PE ratio of -1.56 and a beta of 2.31. The stock has a fifty day simple moving average of $2.31 and a two-hundred day simple moving average of $1.89.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04. On average, sell-side analysts forecast that Context Therapeutics will post -0.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CNTX. Great Point Partners LLC bought a new position in shares of Context Therapeutics during the 2nd quarter valued at about $14,876,000. Blue Owl Capital Holdings LP bought a new position in shares of Context Therapeutics during the 2nd quarter valued at about $10,348,000. Driehaus Capital Management LLC bought a new position in shares of Context Therapeutics during the 2nd quarter valued at about $4,527,000. Nantahala Capital Management LLC bought a new position in shares of Context Therapeutics in the 2nd quarter valued at about $3,881,000. Finally, Affinity Asset Advisors LLC lifted its holdings in shares of Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after acquiring an additional 1,290,323 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.